Characteristics of patients and donors
| . | Treatment group . | |
|---|---|---|
| MP+ . | MP− . | |
| Patients | ||
| Total no. | 53 | 55 |
| Female | 24 | 30 |
| Male | 29 | 25 |
| Age, median (range) | 42 (18-54) | 41 (17-52) |
| Disease | ||
| AML | 22 | 21 |
| CML | 15 | 13 |
| ALL | 5 | 10 |
| MDS | 3 | 6 |
| MM | 4 | 4 |
| NHL | 2 | 1 |
| CLL | 2 | 0 |
| Low risk* | 33 | 37 |
| High risk* | 20 | 18 |
| Conditioning | ||
| TBI | 34 | 34 |
| Busulfan | 19 | 21 |
| Donors | ||
| Female | 16 | 19 |
| Male | 37 | 36 |
| Donor/patient sex | ||
| Different | 26 | 25 |
| Same | 27 | 30 |
| Female to male | 9 | 7 |
| . | Treatment group . | |
|---|---|---|
| MP+ . | MP− . | |
| Patients | ||
| Total no. | 53 | 55 |
| Female | 24 | 30 |
| Male | 29 | 25 |
| Age, median (range) | 42 (18-54) | 41 (17-52) |
| Disease | ||
| AML | 22 | 21 |
| CML | 15 | 13 |
| ALL | 5 | 10 |
| MDS | 3 | 6 |
| MM | 4 | 4 |
| NHL | 2 | 1 |
| CLL | 2 | 0 |
| Low risk* | 33 | 37 |
| High risk* | 20 | 18 |
| Conditioning | ||
| TBI | 34 | 34 |
| Busulfan | 19 | 21 |
| Donors | ||
| Female | 16 | 19 |
| Male | 37 | 36 |
| Donor/patient sex | ||
| Different | 26 | 25 |
| Same | 27 | 30 |
| Female to male | 9 | 7 |
AML indicates acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphatic leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma; CLL, chronic lymphatic leukemia.
Low risk: acute leukemia in first remission or CML in first chronic phase; high risk: all others.